Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00086876" target="_blank" >RIV/00216224:14110/15:00086876 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00209805:_____/15:#0000652
Výsledek na webu
<a href="http://dx.doi.org/10.4149/neo_2015_116" target="_blank" >http://dx.doi.org/10.4149/neo_2015_116</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2015_116" target="_blank" >10.4149/neo_2015_116</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study
Popis výsledku v původním jazyce
Vitamin D deficiency has been implicated in the epidemiology of common malignancies including colorectal cancer. We studied consecutive blood levels of 25-hydroxycholecalciferol (25-OHD) in relation to other clinical and laboratory variables in metastatic colorectal cancer patients to ascertain whether their variations may be prognostic or predictive parameters of survival outcomes. Eighty four patients treated with first-line oxaliplatin-based chemotherapy with or without bevacizumab were included. Thepatients were enrolled on the intent-to-treat basis considering their performance status, comorbidities and laboratory parameters to be medically apt for intensive chemotherapy. Overall survival and progression-free survival were selected as the primaryoutcomes. Progression free survival and overall survival medians were 15.4 months and 41.2 months, respectively.
Název v anglickém jazyce
Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study
Popis výsledku anglicky
Vitamin D deficiency has been implicated in the epidemiology of common malignancies including colorectal cancer. We studied consecutive blood levels of 25-hydroxycholecalciferol (25-OHD) in relation to other clinical and laboratory variables in metastatic colorectal cancer patients to ascertain whether their variations may be prognostic or predictive parameters of survival outcomes. Eighty four patients treated with first-line oxaliplatin-based chemotherapy with or without bevacizumab were included. Thepatients were enrolled on the intent-to-treat basis considering their performance status, comorbidities and laboratory parameters to be medically apt for intensive chemotherapy. Overall survival and progression-free survival were selected as the primaryoutcomes. Progression free survival and overall survival medians were 15.4 months and 41.2 months, respectively.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neoplasma
ISSN
0028-2685
e-ISSN
—
Svazek periodika
62
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
SK - Slovenská republika
Počet stran výsledku
8
Strana od-do
958-965
Kód UT WoS článku
000365931800015
EID výsledku v databázi Scopus
—